• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 13th November 2014

OHE Seminar Launches ‘An EQ-5D-5L Value Set for England’

At an OHE seminar on October 30th, OHE’s Professor Devlin and Professor van Hout from University of Sheffield jointly presented the key results from their study ‘An EQ-5D-5L value set for England’. The seminar was well attended, with participants from…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

At an OHE seminar on October 30th, OHE’s Professor Devlin and Professor van Hout from University of Sheffield jointly presented the key results from their study ‘An EQ-5D-5L value set for England’. The seminar was well attended, with participants from the Department of Health, NICE, NHS England, the EuroQol Group, academia and pharmaceutical industry.

The EQ-5D is widely used to measure and value changes in health-related quality of life. Respondents self-report their health in terms of five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) with three response levels in each (no, some or extreme problems). A new version of the instrument (EQ-5D-5L) with five response levels (no, slight, moderate, severe or extreme problems) is now available. 

A value set is required to link the health states described by the EQ-5D-5L to utility values used in calculating quality-adjusted life years (QALYs). The aim of this project was both to explore theoretical issues relating to how best to elicit and model preferences, and to produce an EQ-5D-5L value set for England.

Professors Devlin and van Hout were awarded a research grant from the Policy Research Programme (PRP) of the National Institute for Health Research (NIHR) for this research. The project team also included Koonal Shah and Yan Feng  from OHE and Brendan Mulhern from the University of Sheffield.

Members of the general public in England (n=996), selected at random from residential post codes, were interviewed by Ipsos MORI between November 2012 and March 2013 using a protocol developed by the EuroQol Group. Each respondent was asked to complete 10 health state valuations using a composite Time Trade Off (TTO) approach, and seven paired comparisons of health states via Discrete Choice Experiment (DCE) tasks. Extensive work was undertaken in modelling the data in alternative ways. The final model selected for the EQ-5D-5L value set for England was a 20 parameter hybrid model (i.e. using both TTO and DCE data) with censored errors/opinions.

The seminar highlighted a number of characteristics of the resulting value set. For example, compared with the EQ-5D value set currently used in the UK, the EQ-5D-5L value set for England:

  • contains a smaller proportion of states with negative values: 3% of health states have negative values (are ‘worse than being dead’), compared to over a third of the health states in the current EQ-5D value set;
  • has a higher minimum value, -0.208, compared to -0.594 in the current EQ-5D UK value set;
  • shows that pain/discomfort and anxiety/depression were the aspects of health people placed most importance on, compared with pain/discomfort and mobility in the current EQ-5D value set;
  • has values which are normally distributed, rather than the ‘bi-modal’ characteristic of the current EQ-5D value set.

Overall, the valuation data have good ‘face validity’. However, it was notable that the responses did not always suggest the respondents saw a difference between ‘level 4’ and ‘level 5’ problems. This is reflected in the corresponding values for anxiety/depression.

Slides from the seminar are available on Slideshare. 

Papers providing details of the methods and results will be released during the coming months.

Further information on the research protocol is available in:

Oppe, M., Devlin, N.., van Hout, B., Krabbe, P. and de Charro, F. (2014) A Program of Methodological Research to Arrive at the New International EQ-5D-5L Valuation Protocol.  Value in Health, 17(4), 445 – 453.

Disclaimer:

The research reported in this seminar is independent research commissioned and funded by the NIHR/ Department of Health Policy Research Programme (‘EQ-5D-5L Value Set for England’ – 070/0073), with additional funding provided by the EuroQol Group. The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health or the EuroQol Group.

  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • Events

Related News

MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
  • News
  • January 2020

OHE Lunchtime Seminar: Personalised Medicine: Is it an oil-rush or oil-spill?

Read more
  • News
  • September 2019

OHE Lunchtime Seminar: Closing the ‘Know-do’ Gap for Health Systems Reform at the Policy Level

Read more
  • News
  • August 2019

OHE Lunchtime Seminar: How Do We Measure the ‘Value’ in Value-based Care?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!